NWBO Stock Chart & Stats
$0.27
>-$0.01(-2.31%)
At close: 4:00 PM EST
$0.27
>-$0.01(-2.31%)
Day’s Range― - ―
52-Week Range$0.14 - $0.37
Previous CloseN/A
Volume1.45M
Average Volume (3M)3.17M
Market Cap
$284.81M
Enterprise Value$374.52M
Total Cash (Recent Filing)$1.79M
Total Debt (Recent Filing)$63.99M
Price to Earnings (P/E)―
Beta1.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,688,074,500
10 Day Avg. Volume4,022,397
30 Day Avg. Volume3,170,177
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-6.97
Price to Sales (P/S)240.49
P/FCF Ratio-7.16
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue250.18
Enterprise Value/Gross Profit-557.33
Enterprise Value/Ebitda-6.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Northwest Biotherapeutics News
NWBO FAQ
What was Northwest Biotherapeutics’s price range in the past 12 months?
Northwest Biotherapeutics lowest stock price was $0.14 and its highest was $0.37 in the past 12 months.
What is Northwest Biotherapeutics’s market cap?
Northwest Biotherapeutics’s market cap is $284.81M.
When is Northwest Biotherapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Northwest Biotherapeutics’s earnings last quarter?
Currently, no data Available
Is Northwest Biotherapeutics overvalued?
According to Wall Street analysts Northwest Biotherapeutics’s price is currently Overvalued.
Does Northwest Biotherapeutics pay dividends?
Northwest Biotherapeutics does not currently pay dividends.
What is Northwest Biotherapeutics’s EPS estimate?
Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Northwest Biotherapeutics have?
Northwest Biotherapeutics has 1,688,074,500 shares outstanding.
What happened to Northwest Biotherapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Northwest Biotherapeutics?
Currently, no hedge funds are holding shares in NWBO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Northwest Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
NWBO Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.6%
Last 30 Days ▲ 17.4%
Last 30 Days ▲ 17.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.87%
12-Months-Change
Fundamentals
Return on Equity
62.41%
Trailing 12-Months
Asset Growth
190.49%
Trailing 12-Months
Company Description
Northwest Biotherapeutics
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
Design Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.06% Other Institutional Investors
99.94% Public Companies and
Individual Investors